TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review

Toll-like receptors 3 (TLR3) have been broadly studied among all TLRs over the last few decades together with its agonists due to their contribution to cancer regression. These agonists undeniably have some shared characteristics such as mimicking dsRNA but pathways through which they exhibit antitu...

Descripción completa

Detalles Bibliográficos
Autores principales: Komal, Asma, Noreen, Mamoona, El-Kott, Attalla F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213534/
https://www.ncbi.nlm.nih.gov/pubmed/34145551
http://dx.doi.org/10.1007/s12026-021-09203-6
_version_ 1783709868687884288
author Komal, Asma
Noreen, Mamoona
El-Kott, Attalla F.
author_facet Komal, Asma
Noreen, Mamoona
El-Kott, Attalla F.
author_sort Komal, Asma
collection PubMed
description Toll-like receptors 3 (TLR3) have been broadly studied among all TLRs over the last few decades together with its agonists due to their contribution to cancer regression. These agonists undeniably have some shared characteristics such as mimicking dsRNA but pathways through which they exhibit antitumor properties are relatively diverse. In this review, three widely studied agonists RGC100, ARNAX, and poly-IC are discussed along with their structural and physiochemical differences including the signaling cascades through which they exert their actions. Comparison has been made to identify the finest agonist with maximum effectivity and the least side effect profile.
format Online
Article
Text
id pubmed-8213534
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-82135342021-06-21 TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review Komal, Asma Noreen, Mamoona El-Kott, Attalla F. Immunol Res Review Toll-like receptors 3 (TLR3) have been broadly studied among all TLRs over the last few decades together with its agonists due to their contribution to cancer regression. These agonists undeniably have some shared characteristics such as mimicking dsRNA but pathways through which they exhibit antitumor properties are relatively diverse. In this review, three widely studied agonists RGC100, ARNAX, and poly-IC are discussed along with their structural and physiochemical differences including the signaling cascades through which they exert their actions. Comparison has been made to identify the finest agonist with maximum effectivity and the least side effect profile. Springer US 2021-06-19 2021 /pmc/articles/PMC8213534/ /pubmed/34145551 http://dx.doi.org/10.1007/s12026-021-09203-6 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Komal, Asma
Noreen, Mamoona
El-Kott, Attalla F.
TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review
title TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review
title_full TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review
title_fullStr TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review
title_full_unstemmed TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review
title_short TLR3 agonists: RGC100, ARNAX, and poly-IC: a comparative review
title_sort tlr3 agonists: rgc100, arnax, and poly-ic: a comparative review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213534/
https://www.ncbi.nlm.nih.gov/pubmed/34145551
http://dx.doi.org/10.1007/s12026-021-09203-6
work_keys_str_mv AT komalasma tlr3agonistsrgc100arnaxandpolyicacomparativereview
AT noreenmamoona tlr3agonistsrgc100arnaxandpolyicacomparativereview
AT elkottattallaf tlr3agonistsrgc100arnaxandpolyicacomparativereview

Ejemplares similares